Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

CytomX is Rallying Today! The Firm Will Report Q1 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

CytomX Therapeutics CytomX Therapeutics, Inc. ( CTMX ) announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets. Following the...

May 1, 2024

Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics in the NEWS On July 15, 2024, Lexeo Therapeutics ( LXEO ) announced positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across both the Lexeo SUNRISE-FA Phase 1/2 clinical trial ( NCT05445323 )...

July 16, 2024

Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News

Regeneron Pharmaceuticals Acquisition of Checkmate Pharmaceuticals Regeneron Pharmaceuticals ( REGN ) announced a successful acquisition of Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology. The firm has added a new modality to the company's portfolio of potential combination-ready approaches for...

May 31, 2022

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Crispr Therapeutics in the NEWS CRISPR Therapeutics ( CRSP ) announced new preclinical data presented at the 27th Annual Meeting of the American Society of Cell and Gene Therapy ( ASGCT ) highlighting the Company’s approach to developing lipid nanoparticle...

May 8, 2024

Jennifer Schneider Elected to Vertex Pharmaceuticals Board of Directors. Why It's Good News

Vertex Pharmaceuticals News Today, May 15, 2024, Vertex Pharmaceuticals ( VRTX ) announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Why is this news Great News? Dr. Schneider has more...

May 15, 2024

Autonomix Medical Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

Autonomix Medical Announcement May 23, 2024, Autonomix Medical ( AMIX ) announced successful completion of an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases and growth. Two groups in a preclinical study of mice received...

May 23, 2024

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

Akero Therapeutics Q2 and Business Update Akero Therapeutics ( AKRO ) reported second-quarter financial results for the period ending June 30, 2024, and provided business updates. From Akero Therapeutics Andrew Cheng, president and CEO said, “The second quarter of 2024...

August 9, 2024

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

CureVac N.V. Files Lawsuit Against BioNTech for Infringement CureVac N.V. ( CVAC ), a company that develops therapeutics based on messenger ribonucleic acid ( mRNA ), has moved to assert its intellectual property rights that have been accumulated over more...

July 5, 2022

Vertex Pharmaceuticals to Acquire ViaCyte Inc to Accelerate its Potentially Curative VX-880 Programs in Type 1 Diabetes

Vertex Pharmaceuticals and ViaCyte Inc are in the NEWS Vertex Pharmaceuticals ( VRTX ) entered into a definitive agreement under which it will acquire ViaCyte, a private biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional...

July 12, 2022

Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences Approval Gilead Sciences ( GILD ) today announced that the U.S. FDA has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis ( PBC ) in combination with ursodeoxycholic acid ( UDCA ) in adults...

August 15, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024